Unlocking Innovation to Advance Cancer Care

Transcription

1 Unlocking Innovation to Advance Cancer Care Liz Barrett, Global President & General Manager, Oncology at Pfizer Remarks for Women in Government November 10, 2017

2 Addressing Significant Unmet Need About half of men and one-third of women in the U.S. will develop cancer in their lifetimes Nearly 1.7 million new cases of breast cancer are diagnosed each year worldwide, including 255,180 in the U.S About one man in seven will be diagnosed with prostate cancer in his lifetime As the leading cause of cancer death worldwide, lung cancer kills 155,870 men and women in the U.S. every year 1/3 of U.S. households report emotional or psychological problems due to cancer and 1/4 say it strains family relationships Sources: American Cancer Society, National Survey of Households Affected by Cancer conducted jointly by USA Today, the Kaiser Family Foundation and the Harvard School of Public Health 2

3 Development of Tumors Normal cells can turn into cancer cells in many ways DNA damage and gene mutations Loss of normal regulation Increases in growth signals from inside and outside NORMAL CELL CANCER CELL 3

4 The Tumor and Its Environment New research has shown that what is going on OUTSIDE the tumor (the microenvironment ) is just as important as what is going in INSIDE the tumor 4

5 The Complexity of Cancer Breast Cancer 5 5

6 Cancer Can Now Be Attacked in More Ways TUMOR FOCUSED TREATMENTS MICRO-ENVIRONMET FOCUSED TREATMENTS Engaging the immune system to help fight tumors Chemotherapy Radiation Therapy Bi-Specific Antibodies Oncolytic Viruses Vaccines ADCs Checkpoint Inhibitors Targeted Therapies CAR-T cells 6

7 Engaging the Immune System Can Be Very Effective Before After 7

8 Five-Year Survival Rate for Breast Cancer Patients 90 5-Year Survival Rate for Patients Diagnosed with Breast Cancer, US UK Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo E Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska- Lasota M, Storm H, Tucker TC, Coleman MP; the CONCORD Working Group. Global surveillance of cancer survival : analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD- 2). Lancet 2015;385(9972):

9 More Cancer Medicines Than Ever Before Today there are more than 825 medicines in development for various types of cancer, up from less than 650 in Source: The Pharmaceutical Research and Manufacturers of America 9

10 Pfizer Oncology Milestones Approved cancer medicines New medicines since 2011 Breakthrough Therapy medicines for 9 Types of cancer including kidney, breast, prostate, and lung Our cutting-edge research has resulted in advances from Precision Medicine to Immuno-Oncology 10

11 Collaborating to Make the Biggest Difference 11

12 Patient Impact 580,000 patients treated with an approved Pfizer Oncology medicine since 2006 Between , Pfizer has helped more than 33,000 uninsured and underinsured patients get access to 148,000 Pfizer Oncology prescriptions 12

13 New Resources to Help Patients 13

14 The Power of Strong State Policy Support Policies That Provide Access to Cancer Screening & Treatment Deaths occur disproportionately among uninsured and underinsured Protect & increase funding and access to screening and treatment programs Support Insurance Policies That Ensure Patient Access to Medicines Clinical efficacy and patient benefit should be given at least as much consideration as cost Healthcare providers must have access tools when a patient s condition warrants it 14

15 Pro-Innovation Policies Can Profoundly Impact Cancer Care Roughly 80% of drugs in development are potential first-inclass medicines The 5-year relative survival rate for all cancers in the U.S. as of 2010 was 68%, up from 49% in the 1970s Between 1988 and 2000, approximately 80-90% of survival gains in a range of cancers were attributable to new treatments, including medicines Sources: Medicines in Development for Cancer. The Pharmaceutical Researchers and Manufacturers of America (PhRMA) and American Association for Cancer Research (AACR) , Cancer Facts & Figures American Cancer Society (ACS) , Sun E, Jena AB, Lakdawalla D, et al. The contributions of improved therapy and early detection to cancer survival gains, Forum Health Econ Policy. 2010;13(2). 15

16 Questions?